RU2014137190A - Комбинации ингибитора гистон-деацетилазы и пазопаниба и их применение - Google Patents
Комбинации ингибитора гистон-деацетилазы и пазопаниба и их применение Download PDFInfo
- Publication number
- RU2014137190A RU2014137190A RU2014137190A RU2014137190A RU2014137190A RU 2014137190 A RU2014137190 A RU 2014137190A RU 2014137190 A RU2014137190 A RU 2014137190A RU 2014137190 A RU2014137190 A RU 2014137190A RU 2014137190 A RU2014137190 A RU 2014137190A
- Authority
- RU
- Russia
- Prior art keywords
- salt
- abexinostat
- cancer
- pazopanib
- combination
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract 30
- MAUCONCHVWBMHK-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)-oxomethyl]phenoxy]ethyl]-2-benzofurancarboxamide Chemical compound O1C2=CC=CC=C2C(CN(C)C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 MAUCONCHVWBMHK-UHFFFAOYSA-N 0.000 claims abstract 20
- 206010028980 Neoplasm Diseases 0.000 claims abstract 18
- 229950008805 abexinostat Drugs 0.000 claims abstract 15
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims abstract 14
- 201000011510 cancer Diseases 0.000 claims abstract 14
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims abstract 14
- 229960000639 pazopanib Drugs 0.000 claims abstract 14
- 206010039491 Sarcoma Diseases 0.000 claims abstract 6
- 150000003840 hydrochlorides Chemical group 0.000 claims abstract 5
- 239000002552 dosage form Substances 0.000 claims abstract 4
- 239000006186 oral dosage form Substances 0.000 claims abstract 3
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims abstract 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims abstract 2
- 208000037844 advanced solid tumor Diseases 0.000 claims abstract 2
- 239000002246 antineoplastic agent Substances 0.000 claims abstract 2
- 201000005787 hematologic cancer Diseases 0.000 claims abstract 2
- 208000037843 metastatic solid tumor Diseases 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 238000011360 adjunctive therapy Methods 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- 229940125683 antiemetic agent Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000011374 additional therapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261600491P | 2012-02-17 | 2012-02-17 | |
| US61/600,491 | 2012-02-17 | ||
| US201261602544P | 2012-02-23 | 2012-02-23 | |
| US61/602,544 | 2012-02-23 | ||
| PCT/US2013/026462 WO2013123413A2 (en) | 2012-02-17 | 2013-02-15 | Combinations of histone deacetylase inhibitor and pazopanib and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014137190A true RU2014137190A (ru) | 2016-04-10 |
Family
ID=48984895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014137190A RU2014137190A (ru) | 2012-02-17 | 2013-02-15 | Комбинации ингибитора гистон-деацетилазы и пазопаниба и их применение |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150335609A1 (enExample) |
| EP (1) | EP2814493A4 (enExample) |
| JP (1) | JP2015507020A (enExample) |
| KR (1) | KR20140129164A (enExample) |
| CN (1) | CN104244952A (enExample) |
| AU (1) | AU2013221298A1 (enExample) |
| CA (1) | CA2864736A1 (enExample) |
| HK (1) | HK1204998A1 (enExample) |
| MX (1) | MX2014009892A (enExample) |
| RU (1) | RU2014137190A (enExample) |
| SG (1) | SG11201404888SA (enExample) |
| WO (1) | WO2013123413A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160303231A1 (en) * | 2013-12-11 | 2016-10-20 | Robert Iannone | Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor |
| WO2017013237A1 (en) | 2015-07-23 | 2017-01-26 | Institut Curie | Use of a combination of dbait molecule and parp inhibitors to treat cancer |
| WO2017053823A1 (en) * | 2015-09-25 | 2017-03-30 | Pharmacyclics Llc | Treatment using hdac inhibitors and immunotherapy |
| EP3612177A4 (en) * | 2017-04-21 | 2021-01-13 | Lunella Biotech, Inc. | TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY |
| JP7227777B2 (ja) * | 2019-02-04 | 2023-02-22 | キヤノン株式会社 | 撮像装置 |
| KR20220018727A (ko) | 2020-08-07 | 2022-02-15 | 계명대학교 산학협력단 | 파조파닙 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 비만 예방 또는 치료용 조성물 |
| WO2022125551A1 (en) * | 2020-12-07 | 2022-06-16 | Hht Foundation International, Inc. | Method of treating hereditary hemorrhagic telangiectasia using pazopanib |
| EP4351734A1 (en) * | 2021-06-10 | 2024-04-17 | Teva Pharmaceuticals International GmbH | Solid state forms of abexinostat and process for preparation thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1611088E (pt) * | 2003-04-07 | 2009-09-24 | Pharmacyclics Inc | Hidroxamatos como agentes terapêuticos |
| JP2007532658A (ja) * | 2004-04-16 | 2007-11-15 | スミスクライン ビーチャム コーポレーション | がんの治療方法 |
| EP2380572A1 (en) * | 2005-11-29 | 2011-10-26 | Glaxosmithkline LLC | Cancer treatment method |
| EP2376081A2 (en) * | 2008-12-15 | 2011-10-19 | Eli Lilly and Company | Enzastaurin for the treatment of cancer |
| US8603521B2 (en) * | 2009-04-17 | 2013-12-10 | Pharmacyclics, Inc. | Formulations of histone deacetylase inhibitor and uses thereof |
| TW201206908A (en) * | 2010-05-05 | 2012-02-16 | Glaxo Wellcome Mfg Pte Ltd | Pharmaceutical compositions and methods of making same |
| AU2012209100A1 (en) * | 2011-01-26 | 2013-08-01 | Board Of Regents The University Of Texas System | Combinations |
-
2013
- 2013-02-15 EP EP13748860.7A patent/EP2814493A4/en not_active Withdrawn
- 2013-02-15 WO PCT/US2013/026462 patent/WO2013123413A2/en not_active Ceased
- 2013-02-15 MX MX2014009892A patent/MX2014009892A/es unknown
- 2013-02-15 KR KR1020147025547A patent/KR20140129164A/ko not_active Withdrawn
- 2013-02-15 SG SG11201404888SA patent/SG11201404888SA/en unknown
- 2013-02-15 AU AU2013221298A patent/AU2013221298A1/en not_active Abandoned
- 2013-02-15 JP JP2014557835A patent/JP2015507020A/ja active Pending
- 2013-02-15 US US14/377,380 patent/US20150335609A1/en not_active Abandoned
- 2013-02-15 HK HK15105968.0A patent/HK1204998A1/xx unknown
- 2013-02-15 CA CA2864736A patent/CA2864736A1/en not_active Abandoned
- 2013-02-15 CN CN201380020595.0A patent/CN104244952A/zh active Pending
- 2013-02-15 RU RU2014137190A patent/RU2014137190A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2864736A1 (en) | 2013-08-22 |
| WO2013123413A2 (en) | 2013-08-22 |
| SG11201404888SA (en) | 2014-09-26 |
| KR20140129164A (ko) | 2014-11-06 |
| JP2015507020A (ja) | 2015-03-05 |
| HK1204998A1 (en) | 2015-12-11 |
| US20150335609A1 (en) | 2015-11-26 |
| EP2814493A4 (en) | 2015-07-22 |
| MX2014009892A (es) | 2015-02-12 |
| EP2814493A2 (en) | 2014-12-24 |
| AU2013221298A1 (en) | 2014-08-28 |
| CN104244952A (zh) | 2014-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125292T1 (el) | Παραγωγα 6,7,8,9-tetpaϋδpo-3h-πypazoλo[4,3-f iσοκινολινης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
| RU2016102158A (ru) | Применение эрибулина и ленватиниба в качестве комбинированной терапии для лечения рака | |
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| HRP20201737T1 (hr) | Metoda za liječenje tumora, farmaceutski sastav i pribor za lijekove | |
| RU2014119713A (ru) | Комбинирование лечения рака | |
| RU2015106524A (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ ИНГИБИТОРА CDK4/6 И ИНГИБИТОРА В-Raf | |
| RU2014141362A (ru) | Комбинированная терапия пролиферативных нарушений | |
| EA201200560A1 (ru) | Специфическая терапия, использующая интегриновые лиганды для лечения рака | |
| RU2015121367A (ru) | Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний | |
| RU2016112608A (ru) | Лечение рака комбинацией плинабулина и таксана | |
| JP2016528162A5 (enExample) | ||
| HK1200716A1 (zh) | 使用胞苷類似物的口服製劑治療癌症的方法 | |
| MX2018016330A (es) | Combinaciones para tratamiento del cáncer. | |
| JP2015507020A5 (enExample) | ||
| EA201491479A1 (ru) | Производные лупановых тритерпеноидов и их фармацевтическое применение | |
| EA201000127A1 (ru) | Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака | |
| RU2014144254A (ru) | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение | |
| RU2011139363A (ru) | Схема лечения рака молочной железы с использованием нератиниба | |
| WO2012142615A3 (en) | Auranofin and auranofin analogs useful to treat proliferative disease and disorders | |
| MX394367B (es) | Moléculas tipo esfingolípidos sintéticas, fármacos, métodos de su síntesis y usos de los mismos. | |
| MX2022012351A (es) | Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres. | |
| RU2015152785A (ru) | Лечение злокачественной опухоли налтрексоном | |
| EA201690321A1 (ru) | Применение иммуноконъюгата антитела к muc1 и майтанзиноида для лечения солидных опухолей | |
| JP2014530181A5 (enExample) | ||
| PH12019502651A1 (en) | Use of vibegron to treat overactive bladder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170703 |